



Spruce Biosciences to Participate in the Jefferies London Healthcare Conference

November 2, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 2, 2023-- [Spruce Biosciences, Inc.](#) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in the Jefferies London Healthcare Conference on November 14-16, 2023.

Archived webcasts from investor conferences are available on the [events section](#) of the company's [investor relations website](#).

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS). To learn more, visit www.sprucebio.com and follow us on Twitter/X @[Spruce Bio](#), [LinkedIn](#), [Facebook](#) and [YouTube](#).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20231102088017/en/>

Media Contact

Will Zasadny
Evoke Canale
(619) 961-8848
will.zasadny@evokegroup.com
media@sprucebio.com

Investors

Samir Gharib
President and CFO
Spruce Biosciences
investors@sprucebio.com

Source: Spruce Biosciences, Inc.